1. Clinically relevant bleeding was significantly lower with ticagrelor monotherapy than in the ticagrelor plus aspirin group. 2. Major cardiovascular and cerebrovascular events were comparable in both groups. Evidence Rating Level: 1 (Excellent) Study Rundown: Dual antiplatelet therapy (DAPT) is the current standard of care for acute coronary syndrome (ACS) following percutaneous coronary intervention (PCI).
1. Target-vessel failure was significantly lower in the ultrasound-guided group than the angiography-guided group. 2. There was no significant difference between groups concerning stent thrombosis. Evidence Rating Level: 1 (Excellent) Study Rundown: Angiography-guided percutaneous coronary intervention (PCI) is the current standard of care for patients with coronary artery stenosis, although this is associated with complications.
1. Overall vaccine efficacy ranged from 83.1% to 86.6% during the 10-year period. 2. Detectable concentrations of antibodies persisted at the 8.5-year mark in Qindong. Evidence Rating Level: 1 (Excellent) Study Rundown: Hepatitis E virus (HEV) is a leading cause of acute viral hepatitis worldwide. Currently, two recombinant HEV vaccines exist; however, little is known
1. Aflibercept 8 mg was non-inferior to 2 mg for best-corrected visual acuity at 48 weeks. 2. Ocular adverse events were comparable across treatment groups. Evidence Rating Level: 1 (Excellent) Study Rundown: Neovascular age-related macular degeneration (nAMD) is a major cause of vision loss worldwide. Anti-vascular endothelial growth factors, such as aflibercept, may improve treatment
1. Overall vaccine efficacy ranged from 83.1% to 86.6% during the 10-year period. 2. Detectable concentrations of antibodies persisted at the 8.5-year mark in Qindong. Evidence Rating Level: 1 (Excellent) Study Rundown: Hepatitis E virus (HEV) is a leading cause of acute viral hepatitis worldwide. Currently, two recombinant HEV vaccines exist; however, little is known